Vitiligo progression in a patient undergoing romosozumab treatment for osteoporosis.
JAAD Case Rep
; 42: 26-30, 2023 Dec.
Article
in En
| MEDLINE
| ID: mdl-37965188
BMP6; Dynein light chain Tctex-type 3; Dynlt3; LRP5; LRP6; Monoclonal; Pathway; RANKL; Romosozumab; Signaling; Wnt; activity; adverse effect; antibody; bone morphogenetic protein 6; flare; injection; low-density lipoprotein receptor-related protein 5; low-density lipoprotein receptor-related protein 6; medication; osteoporosis; progression; receptor activator of nuclear factor κB ligand; sclerostin; vitiligo; ß-catenin
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
JAAD Case Rep
Year:
2023
Document type:
Article
Country of publication:
United States